Robert Broyles received $218,000 to advance his business, and he aims to turn it into more than $1 million for Oklahoma City-based EpimedX.
News
Robert Broyles, in his work at the OU Health Science Center and National Institutes of Health, discovered that a molecule called ferritin-H would likely cause the switch back to fetal hemoglobin.
Local biotech startup EpimedX believes a drug known as Edx-17 could help treat annually more than 90,000 patients with sickle cell disease in the U.S.
